Get the Stockscreener App
12.43
4.37%
0.52
Novocure Ltd stock is traded at $12.43, with a volume of 1.44M.
It is up +4.37% in the last 24 hours and down -23.74% over the past month.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
See More
Previous Close:
$11.91
Open:
$12.08
24h Volume:
1.44M
Relative Volume:
0.89
Market Cap:
$1.39B
Revenue:
$577.74M
Net Income/Loss:
$-149.78M
P/E Ratio:
-8.8786
EPS:
-1.4
Net Cash Flow:
$-78.21M
1W Performance:
+5.97%
1M Performance:
-23.74%
6M Performance:
-43.73%
1Y Performance:
-26.84%
1-Day Range:
$11.96
$12.47
1-Week Range:
$11.55
$12.47
52-Week Range:
$10.87
$34.13
Novocure Ltd Stock (NVCR) Company Profile
Name
Novocure Ltd
Sector
Industry
Phone
44 (0)15 3475 6700
Address
NO. 4 THE FORUM, ST. HELIER
Compare NVCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
12.43 | 1.35B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
132.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.17 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.22 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.71 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
81.83 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Dec-02-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-28-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-08-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-04-23 | Initiated | SVB Securities | Outperform |
| Jul-31-23 | Upgrade | Evercore ISI | Underperform → In-line |
| Jun-07-23 | Upgrade | Wedbush | Underperform → Neutral |
| May-16-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-06-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-05-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-29-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-24-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-05-22 | Downgrade | Evercore ISI | In-line → Underperform |
| May-16-22 | Initiated | H.C. Wainwright | Buy |
| Feb-08-22 | Initiated | Loop Capital | Buy |
| Feb-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| Jan-03-22 | Upgrade | Evercore ISI | Underperform → In-line |
| Jul-01-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-14-21 | Downgrade | Wedbush | Neutral → Underperform |
| Jan-25-21 | Reiterated | Piper Sandler | Overweight |
| Sep-23-20 | Initiated | Northland Capital | Outperform |
| Sep-18-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-17-20 | Downgrade | Truist | Buy → Hold |
| Jun-01-20 | Resumed | Oppenheimer | Perform |
| May-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-09-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Mar-05-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-29-19 | Upgrade | SunTrust | Hold → Buy |
| Jul-26-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-19 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-20-19 | Initiated | SunTrust | Hold |
| Nov-02-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jul-16-18 | Initiated | Evercore ISI | Outperform |
| Apr-18-18 | Reiterated | Mizuho | Buy |
| Feb-23-18 | Reiterated | Mizuho | Buy |
| May-24-17 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Jul-29-16 | Reiterated | Wedbush | Outperform |
| Jan-19-16 | Initiated | Barclays | Underweight |
| Dec-02-15 | Initiated | Deutsche Bank | Hold |
View All
Novocure Ltd Stock (NVCR) Latest News
Novocure seeks FDA approval for pancreatic cancer treatment - Investing.com
Breakthrough Pancreatic Cancer Treatment: Novocure's TTFields Therapy Seeks FDA Approval After Success - Stock Titan
Using R and stats models for NovoCure Limited forecastingOil Prices & Weekly Top Gainers Trade List - Newser
Is NovoCure's (NVCR) Rising Active Patient Count Reshaping Its Investment Case? - simplywall.st
Leerink Partners Reiterates a Buy Rating on NovoCure Limited (NVCR) - Yahoo Finance
Statistical indicators supporting NovoCure Limited’s strengthFree Watchlist for Low Risk High Return - Newser
Novocure stock hits 52-week low at 10.88 USD By Investing.com - Investing.com Nigeria
Novocure stock hits 52-week low at 10.88 USD - Investing.com
NovoCure's Optune Study for Glioblastoma Treatment: A Potential Game-Changer in the Market - AInvest
Is NovoCure Limited trending in predictive chart modelsAsset Growth Pattern and Return Summary - Newser
Short interest data insights for NovoCure LimitedTechnical Confirmation System with Signal Alerts - Newser
Detecting price anomalies in NovoCure Limited with AILow Drawdown Stock Screener with Analysis - Newser
NovoCure’s Pivotal Study on Optune® for Glioblastoma: A Market Game-Changer? - TipRanks
Real time scanner hits for NovoCure Limited explainedAI Short-Term Gain Forecast with Data - Newser
How institutional ownership impacts NovoCure Limited stockFree Triple Digit Return Stock Predictions - Newser
How strong is NovoCure Limited company’s balance sheetRapid wealth multiplication - Jammu Links News
What are analysts’ price targets for NovoCure Limited in the next 12 monthsCapitalize on emerging market sectors - Jammu Links News
How volatile is NovoCure Limited stock compared to the marketBreakthrough profit margins - Jammu Links News
Is NovoCure Limited stock poised for growthAnnual Market Behavior and Sector Summary - Newser
Chief Financial Officer of NovoCure Christoph Brackmann Buys 339% More Shares - simplywall.st
NovoCure (NVCR) Sales Rise but Losses Deepen—Is Profitability or Growth the Bigger Priority? - simplywall.st
NovoCure (NASDAQ:NVCR) Shares Up 9.3% After Insider Buying Activity - Defense World
Novocure’s Earnings Call: Clinical Successes & Cautious Optimism - TipRanks
NovoCure CFO Makes a Bold Move: Christoph Brackmann Purchases $231,800 Worth of Stock - AInvest
NovoCure: Cash Burn, A Costly Launch, And A Maturing Business Signal More Pain Ahead - Seeking Alpha
Will NovoCure Limited stock benefit from AI tech trendsWeekly Entry Signal Based Forecast Tool - Newser
Multi asset correlation models including NovoCure LimitedFree Low Risk Buy Zone Opportunity Watch - Newser
Why NovoCure Stock Is Cratering Today - Mitrade
NovoCure Limited (NASDAQ:NVCR) Q2 2025 Earnings Call Transcript - Insider Monkey
Does NovoCure Limited show high probability of reboundSafe Entry Strategy with High Win Rate - Newser
What are NovoCure Limited company’s key revenue driversDiscover undervalued stocks before they soar - Jammu Links News
Top 3 Health Care Stocks That May Explode In July - inkl
Wells Fargo & Company Reaffirms Equal Weight Rating for NovoCure (NASDAQ:NVCR) - Defense World
NovoCure Q2 2025 Earnings Highlights: Revenue Growth Amidst Challenges - AInvest
NovoCure Second Quarter 2025 Earnings: Beats Expectations - simplywall.st
NovoCure: Q2 Earnings Snapshot - Norwalk Hour
Novocure Beat Revenue Expectations As Patient Numbers Grew - Finimize
NovoCure Limited 2025 Q2ResultsEarnings Call Presentation (NASDAQ:NVCR) - Seeking Alpha
Bank of New York Mellon Corp Grows Stake in NovoCure Limited (NASDAQ:NVCR) - Defense World
Wells Fargo Downgrades NovoCure (NVCR) with Significant Price Ta - GuruFocus
Novocure Ltd Stock (NVCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Novocure Ltd Stock (NVCR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Stafford Kristin | Director |
Jun 03 '25 |
Sale |
17.28 |
999 |
17,259 |
3,054 |
| LEUNG GABRIEL | Director |
Jun 03 '25 |
Sale |
17.31 |
999 |
17,297 |
81,229 |
| Madden Martin J. | Director |
Jun 03 '25 |
Sale |
17.19 |
999 |
17,176 |
18,674 |
| Scannell Timothy J | Director |
Jun 03 '25 |
Sale |
17.32 |
999 |
17,299 |
6,018 |
| HILLEMAN JERYL L | Director |
Jun 03 '25 |
Sale |
17.26 |
999 |
17,247 |
5,591 |
| Ocean Allyson J | Director |
Jun 03 '25 |
Sale |
17.29 |
999 |
17,269 |
3,054 |
| VERNON W ANTHONY | Director |
Jun 03 '25 |
Sale |
17.35 |
999 |
17,329 |
167,887 |
| Hung David | Director |
Jun 03 '25 |
Sale |
17.30 |
999 |
17,280 |
12,195 |
| Leonard Frank X | EVP, Pres., Novocure Oncology |
Jun 02 '25 |
Sale |
17.50 |
30,196 |
528,413 |
168,452 |
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):